HOT TOPICS - ANNEXA-I Trial
Neurocritical Care Society Podcast
00:00
Reversal Agents and Clinical Outcomes in ICH Cases
The chapter analyzes the findings of the ANNEXA-I Trial on indexing alpha for factor Xa inhibitors, exploring its impact on hematoma expansion and functional outcomes. The debate on whether preventing hematoma expansion leads to improved clinical benefits and weighing the risks of ischemic stroke alongside the benefits are key points of discussion. The chapter also covers the Enrich AF trial and the importance of personalized treatment decisions in balancing thrombotic risk reduction and preventing hematoma expansion.
Transcript
Play full episode
